J.P. Morgan Notebook, Jan. 15: Kite, Vivus, Amarin
This article was originally published in The Pink Sheet Daily
“The Pink Sheet” DAILY’s round-up of news and notes from the last day of the J.P. Morgan Healthcare Conference in San Francisco.
You may also be interested in...
Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the first day of the 2015 J.P. Morgan Healthcare Conference in San Francisco.
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.